#CancerImmunotherapy
LightNews LightNews
tenuretracker.bsky.social
University of North Carolina is hiring:
Senior Research Scientist

#researcher #medicine #cancerimmunotherapy
November 3, 2026 at 2:39 PM
crijournal.bsky.social
Allogeneic Dendritic Cells: Transforming the Impact of Cancer Immunotherapy

www.dl.begellhouse.com/journals/2ff...

#DendriticCells #CancerImmunotherapy #CellTherapy
October 30, 2026 at 7:00 PM
cellreprolab.bsky.social
The transformative concept of cellular reprogramming is now being applied for in vivo cancer immunotherapy. How might the next 20 years expand reprogramming approaches within the tumor microenvironment? Exciting times ahead!
#iPSC #CellularReprogramming #CancerImmunotherapy
October 30, 2026 at 12:13 PM
crijournal.bsky.social
Supercharged NK Cells: A Novel NK Cell-Based Immunotherapy to Target Poorly Differentiated and Well-Differentiated Uterine Cancers

www.dl.begellhouse.com/journals/2ff...

#UterineCancer #NKCellTherapy #CancerImmunotherapy
October 29, 2026 at 7:00 PM
scholarcast.bsky.social
Nano-biohybrid KBTO-VNP pairs tumor-targeting Salmonella with sonosensitizer nanoparticles: ultrasound-controlled bacterial clearance, deep tumor penetration & potent immunotherapy, >96% tumor inhibition. doi.org/10.1002/bmm2...
#BacterialTherapy #SonodynamicTherapy #CancerImmunotherapy
Bacterial backpacks for targeted delivery of piezoelectric nanoparticles to enhance sonodynamic immunotherapy
Leveraging bacterial hypoxia targeting, KBTO NPs accumulate at the tumor site. Under the ultrasound irradiation, KBTO NPs produce reactive oxygen species to kill tumor cells and eliminate bacteria, p....
doi.org
November 3, 2026 at 8:09 AM
myesmo.bsky.social
#ESMO26: Antoni Ribas receives the 2026 ESMO Lifetime Achievement Award for his significant contributions to #CancerResearch and #CancerImmunotherapy, which have led to groundbreaking therapies becoming part of #ClinicalPractice.
➡️ https://ow.ly/yxME50ZZize

#InsightsbyESMO
October 23, 2026 at 12:00 PM
sciencecareers.bsky.social
How can nanoscale design overcome biological barriers in cancer treatment?

📅 Join the 2026 Westlake × @science.org Symposium #4: Nanoscale Therapeutics on Oct. 22 at 8:00 AM ET.

Register: https://bit.ly/4yQnFau

#Nanomedicine #CancerImmunotherapy
The image is a promotional graphic for "Nanoscale Therapeutics," part of the 2026 Westlake x Science Symposia. It features vibrant, stylized illustrations of molecules or cells. The event details are listed, including dates and times for different regions. Logos for Science, AAAS, Westlake University, and the School of Engineering are displayed at the top.
October 20, 2026 at 2:00 AM
csbj.org
🔗 Computational Design of a TCR-like Human VH Domain Antibody That Specifically Recognizes a WT1-Derived Peptide Presented by Class I Major Histocompatibility Complex. doi.org/10.34133/csb...

📚 CSBJ - A Science Partner Journal: spj.science.org/journal/csbj

@csbj.org #CancerImmunotherapy #Oncology
🔗 Computational Design of a TCR-like Human VH Domain Antibody That Specifically Recognizes a WT1-Derived Peptide Presented by Class I Major Histocompatibility Complex. Computational and Structural Biotechnology Journal (CSBJ). DOI: https://doi.org/10.34133/csbj.0236 📚 CSBJ - A Science Partner Journal: https://spj.science.org/journal/csbj
October 17, 2026 at 2:07 AM
tenuretracker.bsky.social
University of California, Los Angeles (UCLA) (@ucla.edu) is hiring:
Postdoctoral Scholar in RNA-Lipid Nanoparticle Cancer Immunotherapy

#postdoc #medicine #cancerimmunotherapy
October 15, 2026 at 12:13 PM
sciencecareers.bsky.social
How can nanoscale design overcome biological barriers in cancer treatment?

📅 Join the 2026 Westlake × @science.org Symposium #4: Nanoscale Therapeutics on Oct. 22 at 8:00 AM ET.

Register: https://bit.ly/4yQnFau

#Nanomedicine #CancerImmunotherapy
The image is a promotional graphic for "Nanoscale Therapeutics," part of the 2026 Westlake x Science Symposia. It features vibrant, stylized illustrations of molecules or cells. The event details are listed, including dates and times for different regions. Logos for Science, AAAS, Westlake University, and the School of Engineering are displayed at the top.
October 14, 2026 at 2:02 PM
amjtransplant.bsky.social
Introducing our new feature, AJT Catalyst!
buff.ly/HlAxrBr
This month, read "Antibody-cytokine fusion enables spatially targeted modification of immune responses to tumors" by EM Gillis Buck et al
buff.ly/Iq1f7NT
#Immunotherapy #Cytokines #CancerImmunotherapy
AJT Catalyst logo
October 12, 2026 at 12:15 PM
biomedicines.bsky.social
🧬 A novel lipopeptide suppressed both melanoma & psoriasis in immunocompetent mice. Findings suggest it may help balance anticancer immunity and immune tolerance, offering a potential new approach in cancer immunotherapy. ⚖️ #CancerImmunotherapy
www.mdpi.com/2227-9059/13...
October 7, 2026 at 9:02 AM
gmj-georgia.bsky.social
🔬 mRNA cancer vaccines use an unexpected immune backup system that scientists didn't know about until now. This discovery could lead to…

#Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcology #Vaccinedevelopment

#Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcolog…
mRNA Vaccines' Hidden Immune Backup System
🔬 mRNA cancer vaccines use an unexpected immune backup system that scientists didn't know about until now. This discovery could lead to… #Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcology #Vaccinedevelopment
news.gmj.ge
October 1, 2026 at 9:26 AM
uoustanford.bsky.social
Orca-T represents a milestone in cancer research, making stem cell transplants safer for blood cancer patients by using the immune system with greater precision to open new possibilities across oncology.

Learn more: med.stanford.edu/cancer/about...

#StanfordMedicine #CancerImmunotherapy
September 27, 2026 at 2:21 PM
gmj-georgia.bsky.social
New laboratory research reveals creatine may strengthen cancer-fighting immune pathways by energizing dendritic cells that activate killer T c…

#Cancerimmunotherapy #Creatine #Dendriticcells #Immunemetabolism #Translationalresearch

#Cancerimmunotherapy #Creatine #Dendriticcells #Immunemetabolis…
Can Creatine Enhance Cancer Immunity?
New laboratory research reveals creatine may strengthen cancer-fighting immune pathways by energizing dendritic cells that activate killer T c… #Cancerimmunotherapy #Creatine #Dendriticcells #Immunemetabolism #Translationalresearch
news.gmj.ge
September 24, 2026 at 9:26 PM
gmj-georgia.bsky.social
New phase 2 trial data: Teclistamab-based induction therapy achieves deep remissions in transplant-eligible newly diagnosed multiple myeloma…

#BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematology

#BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematolo…
Teclistamab Achieves Deep Myeloma Remissions
New phase 2 trial data: Teclistamab-based induction therapy achieves deep remissions in transplant-eligible newly diagnosed multiple myeloma… #BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematology
news.gmj.ge
September 21, 2026 at 5:26 PM
sigtrans-sttt.bsky.social
Researchers evaluate the novel PARP inhibitor prodrug TSL-1502 in a phase 2 trial, demonstrating promising antitumor activity in BRCA-mutated HER2-negative advanced breast cancer. #ClinicalTrial

#STTT #OpenAccess: doi.org/10.1038/s413...
#CellTherapy #CancerImmunotherapy
September 21, 2026 at 4:20 PM
gpbees.bsky.social
6/ 💡 Together, the study expands the landscape of potential HCC antigens beyond the canonical proteome and provides a framework for discovering and validating ncORF-derived targets for cancer immunotherapy.

#LiverCancer #HCC #CancerImmunotherapy #Immunopeptidomics
September 21, 2026 at 3:05 PM
alicefrolov.bsky.social
Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade.

#TcellExhaustion #CheckpointBlockade #TumorImmunology #CD8Tcells #AntiPD1 #Tpex #ImmuneCheckpoint #CancerImmunotherapy
Sharing a new data visualization exploring the phenotypic reprogramming of exhausted CD8+ T cells following PD-1 axis blockade. Figure: "Reprogramming exhausted CD8+ T cells with anti-PD-1 therapy" Subtitle: "Marker-defined transitions from terminal exhaustion toward progenitor/effector states after checkpoint blockade" The visualization employs a faceted marginal-distribution slope arrow design, functioning as a state-transition flow map. Each facet corresponds to a defined exhaustion-associated marker axis (TCF1, TOX, TIM-3, PD-1, GZMB, and Ki-67), with paired marginal distributions rendered pre- and post-treatment. Slope arrows connect the density centroids across conditions, encoding both the directionality and relative magnitude of population-level marker shifts. This approach was chosen to make explicit the differential mobilization of progenitor-exhausted (Tpex) versus terminally exhausted (Tex_term) subsets rather than collapsing the transition into a single trajectory summary. The simulated data are calibrated to reproduce trends consistent with the current literature. Under anti-PD-1, the TCF1+ TOX-intermediate progenitor compartment shows expansion accompanied by upward slope vectors in Ki-67 and GZMB, consistent with proliferative burst and reacquisition of effector potential. Concurrently, the TIM-3-high, TCF1-negative terminally differentiated fraction contracts, and its centroid displays limited displacement along the TCF1 axis, reflecting the constrained plasticity of terminally exhausted cells. This asymmetry underscores that checkpoint blockade preferentially acts on the Tpex reservoir rather than fully reverting terminal exhaustion, a distinction with direct implications for durability of response.
September 12, 2026 at 5:18 PM
mdpipharma.bsky.social
🧬 Natural product immunotherapies in 3D tumor models—penetration vs activity. This review says: don't chase depth, preserve activity at peripheral immune cells. New evaluation framework inside!

📌 www.mdpi.com/1999-4923/17...

#CancerImmunotherapy #NaturalProducts #3DModels
September 11, 2026 at 10:27 AM
genesndiseases.bsky.social
Better #CancerImmunotherapy requires tackling hidden immune barriers.
This review highlights how dysfunctional #Bcells suppress anti-tumor immunity and outlines strategies to reprogram the #TumorMicroenvironment.
#OpenAccess in #GenesAndDiseases: doi.org/10.1016/j.ge...
September 11, 2026 at 2:00 AM
gmj-georgia.bsky.social
New phase 2 trial data: Teclistamab-based induction therapy achieves deep remissions in transplant-eligible newly diagnosed multiple myeloma…

#BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematology

#BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematolo…
Teclistamab Achieves Deep Myeloma Remissions
New phase 2 trial data: Teclistamab-based induction therapy achieves deep remissions in transplant-eligible newly diagnosed multiple myeloma… #BCMA #Bispecificantibodies #Cancerimmunotherapy #Clinicaltrials #Haematology
news.gmj.ge
September 10, 2026 at 8:41 PM
jem.org
The transcription factor IRF8 drives tumor-specific exhaustion in CD8⁺ T Cells. From Marco Ongaro, Grégory Verdeil and colleagues: rupress.org/jem/article/...

Part of our #CancerImmunotherapy 2026
👉 rupress.org/jem/collecti...
#CSHAsia
September 11, 2026 at 12:01 AM
sigtrans-sttt.bsky.social
Which noncanonical tumor antigens can be translated into T-cell targets?

EVA003 emerges as a #Melanoma-enriched antigen whose HLA-A*03:01-presented peptide is recognized by a natural TCR that directs melanoma cell killing.

#STTT #OpenAccess: doi.org/10.1038/s413...
#CancerImmunotherapy
Receptor-defined targeting of a genomically unique melanoma-enriched noncanonical antigen
September 10, 2026 at 11:45 AM